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Purpose:Percutaneous radiofrequency thermalablation (RTA)was reportedasaneffective tool for
the management of thyroid nodules (TNs). The aim of this study was to investigate the effects of
RTA and to establish whether they were treatment-related by comparison with a matched, un-
treated control group.
Patients and Methods: The study population included 40 patients with compressive TNs: 22 had
nontoxic TNs, and 18 had toxic TNs and were treated with methimazole. In all patients, a fine-
needle aspiration cytology was performed to exclude a thyroid malignancy.
StudyDesign: Twenty patients were treatedwith RTA (groupA), and 20 others did not receive any
treatment (groupB). At baseline, age, gender, andTN features did not differ significantly between
groups. All patients were clinically, biochemically, and morphologically evaluated at baseline and
after 1, 3, 6, and 12 months.
Results: TN volume significantly decreased in group A (1.8 0.3 ml at 12 months vs. 13.3 1.8 ml
at baseline; P 0.0001) and remained stable in group B [11.7 1.5 ml at 12 months vs. 11.2 1.5
ml at baseline; P  not significant (NS)]. At 3-, 6-, and 12-month evaluations, TN volume was
significantly lower in group A than in group B (P  0.005). At the end of the follow-up, pressure
symptoms were improved in all patients in group A but persisted unchanged in group B. In group
A, hyperthyroidism completely recovered in 40% and improved in 40% of patients with toxic TNs,
whereas it persisted in all patients with toxic TNs in group B. RTAwas safe andwell tolerated in all
patients.
Conclusions: RTA induced a marked TN volume shrinkage resulting in parallel improvement of
pressure symptoms. Inmostpatientswith toxic TNs,hyperthyroidismsignificantly improvedaswell.
RTA may represent a valid therapeutic approach in patients with TNs not receiving conventional
treatments. (J Clin Endocrinol Metab 97: 0000–0000, 2012)
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Thyroid nodules (TNs) are very common in the generalpopulation, with a prevalence of about 50% in sub-
jects older than 60 yr undergoing neck ultrasound exam-
ination (1).
The great majority of TNs are benign, but they can be
responsible for pressure symptoms in the neck and can result
in discomfort and decreased quality of life. Large compres-
sive TNsmay result in life-threatening conditions because of
the potential acute onset of respiratory crisis. Thyroid sur-
gery and radioiodine therapy are the main therapeutic ap-
proaches for compressiveTNs (1–3). Surgical complications
(both temporary and permanent) are usually reported in
7–10% of cases (4), but the risk of mortality and morbidity
for thyroid surgery is sensibly greater in elderly patients due
to frequent comorbidity (5, 6). Finally, part of the TN pa-
tients fulfilling criteria for surgery refuse this approach. In
some of these cases, radioiodine therapy may be ineffective,
especially for large non-hyperfunctioning TNs (6–8). Min-
imally invasive therapeutic options have been proposed to
treat TNs when surgery or radioiodine is refused, contrain-
dicated, or ineffective (9).
Percutaneous radiofrequency thermal ablation (RTA)
is aminimally invasive procedure that has been developed
first to treat patients with liver cancer and has then been
used to treat both malignant and benign tumor nodules in
many organs (10–14). RTA also represents a promising
new approach for the management of TNs (15, 16).
In a previous study, we demonstrated the efficacy and
safety of RTA in the treatment of TNs with local pressure
symptoms in 39 elderly patients. The benefit-risk ratio
appeared elevated, suggesting that this approachmay rep-
resent a valid alternative in subjects who refuse orwho are
not candidates for conventional treatments (15). A 2-yr
follow-up study showed that RTA is highly effective in
achieving long-term shrinkageof large solidTNsaswell as
in controlling TN-related symptoms in a large series of
elderly subjects with compressive TNs (16).
Some other studies further investigated the role of
RTA in patients with TNs (15–21), but only one study
evaluated the effectiveness of RTA in a comparative
setting (22). In this study, Baek et al. (22) performed
RTA by using a single-hook 18-gauge needle in 15 pa-
tients with benign, nontoxic, predominantly solid TNs.
A 6-month follow-up highlighted that the observed TN
volume shrinkage was related to RTA activity rather
than spontaneous reduction (22).
The current prospective comparative study aims to in-
vestigate the long-term effectiveness of RTA in patients
with TNs. Both toxic and nontoxic TNswill be evaluated.
Patients and Methods
Study population
Fortyconsecutivepatients (31womenand9men;age,31–86yr)
with solid or predominantly solid (cystic component30%), large
(4.0ml)TNswithpressuresymptomsthatwerefollowedupatthe
Department of Molecular and Clinical Endocrinology and Oncol-
ogy,“FedericoII”UniversityofNaples,wereprospectivelyenrolled
in this study between January 2010 and June 2011. Two patients
had unsuccessful surgery, and two other patients had unsuccessful
radioactive iodine therapy with 131I.
Twenty-two patients had nontoxic TNs, and 18 patients
had toxic TNs and were treated with antithyroid drugs
(methimazole).
Study design
All patients had a complete clinical, hormonal, and B-mode
ultrasonography (US) evaluation. To rule out a thyroid malig-
nancy, a US-guided fine-needle aspiration cytology (FNC) was
performed on all nodules larger than 1 cm (or less in the presence
of US characteristics suspected for malignancy).
As a whole, 44 consecutive subjects with TNs were cytolog-
ically evaluated. Four patients were excluded because they had
one of the following FNC categories: atypical, follicular neo-
plasm or suspicious for a follicular neoplasm, suspicious for ma-
lignancy, malignant, according to the Bethesda classification
(23). Three patients underwent a second FNC evaluation due to
nondiagnostic or unsatisfactory cytological specimen. All pa-
tients enrolled in the study had benign TNs, negative for malig-
nant cells at the FNC evaluation. Patients enrolled in the study
were randomized as follows: 20 patients were treated with a
TABLE 1. Baseline characteristics of patients with TNs
Parameter Group A Group B P
n 20 20 NS
Sex (males/females) 4/16 5/15 NS
Age in years, mean  SEM (range) 58.3  4.3 (31–86) 62.1  3.1 (36–85) NS
TN volume (ml)
Mean  SEM 13.3  1.8 11.2  1.5 NS
Median 12.35 7.7
Range 4–27.9 3.6–25.8
Patients with nontoxic TNs (n) 10 12 NS
Patients with toxic TNs (n) 10 8 NS
SYS score (range) 3.4  0.3 (1–5) 3.0  0.3 (1–5) NS
Group A, Patients treated with RTA; group B, patients not treated. Statistical analysis was performed by using ANOVA. SYS score, Symptom score
expressed as the sum of the single scores including pressure symptoms in the neck, difficulty in swallowing, esthetic complaint.
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singleRTA session (groupA), and20patients did not receive any
treatment and were only followed up (group B). In group A, 10
patients had nontoxic TNs, and 10 patients had toxic TNs. In
groupB, 12patients hadnontoxicTNs, and eight had toxicTNs.
Inclusion criteria were: age above 18 yr; benign TNs (Thy2);
solid or predominantly solid (cystic component  30%) large
(4.0 ml) TNs; and refusal and/or inefficacy of surgery and/or
radioiodine therapy. Exclusion criteria were pregnancy and ma-
lignant or suspicious TNs. One nodule per patient was treated
with RTA. If a patient had multiple TNs, the largest and most
symptomatic one was treated. All patients were clinically, bio-
chemically, and morphologically evaluated at 1, 3, 6, and 12
months after treatment in group A and parallel in group B. Base-
line characteristics of patients in groupA and group B are shown
in Table 1. Age, gender, TN volume, function, and ultrasono-
graphic characteristics did not differ significantly between
groups at baseline (Table 1).
The protocol for this study was approved by the Hospital
Ethics Committee, and all patients provided written, informed
consent before participating in the study (registration no.
NCT01649206).
Methods
Clinical evaluation
The TN-related neck symptom score used in the study in-
cluded pressure symptoms in the neck, difficulty in swallowing,
or esthetic complaints, as previously described and validated in
a study quantifying the clinical response of patients with TNs to
ethanol injection (24). Symptoms were scored separately as fol-
lows: 0 (absent), 1 (moderate), and 2 (severe). The sum of the
individual scores generated a final score (SYS score) ranging
from 0 to 6 (24).
Biochemical evaluation
SerumconcentrationsofTSH, freeT4, free
T3, thyroglobulin, and calcitonin, as well as
titers of antithyroglobulin (TgAb) and anti-
thyroperoxidase antibodies (TPOAb) were
measured at baseline. TSH, free T4, free T3,
thyroglobulin, TgAb, and TPOAb were also
measured at 1-, 3-, 6-, and 12-month
follow-up.
US evaluation
USwas performed using a 7.5–12MHz
linear probe equipped with CD and PD
modules (Technos MPX; Esaote Bio-
medica, Genova, Italy). Three orthogonal
dimensions of TNs were measured on US
scans and used to calculate the TN volume
through the following ellipsoid equation:
lengthwidth depth 0.525. A single
TN volume was measured in case of uni-
nodular goiter or in case of multinodular
goiter when characterized by one predom-
inant nodule associated with other non-
clinically significant TNs. In cases of two
or more nodules that were confluent in a
compressive lobar mass, the volume of
the whole mass within the lobe was
considered.
Radiofrequency thermal ablation
Percutaneous RTA was carried out using a RITA StarBurst
Talon needle (RITA Medical Systems, Fremont, CA) inserted
under ultrasonographic guidance. The needle was 14-gauge and
10 cm long and was made up of four hooks expandable to 4 cm.
This needle was inserted into each nodule. The hooks were then
opened to a maximum of 3.5 cmwith an exposure time variable
between 5 and 7min, reaching amaximum temperature variable
between 101 and 105 C. After careful cleaning, 2.0–4.0 ml of
2% lidocaine (Xilocaine 2%; AstraZeneca, Basiglio, Italy) was
slowly injected into superficial cervical tissue and on the thyroid
gland capsule under US guidance. During the RTA procedure,
the correct placement of the needle tip, the position of the hooks,
and the characteristics and diameters of each RTA-induced le-
sion were assessed by US. After the procedure, the hooks were
retracted, and the needle was slowly pulled out with the radio-
frequency energy off. All patients received ice to put on the neck
with mild compression and were observed for about 2 h.
Statistical analysis
The statistical analysis was performed by SPSS for Windows
version 15.0 (SPSS, Inc., Chicago, IL). Data are reported as
mean  SEM. The significance was set at 5% (P  0.05). The
comparisons between the numerical data were performed by the
ANOVA test.
Results
The results of RTA are evaluated by change in TN volume
and thyroid function and improvement in clinical symp-
toms (SYS score).
FIG. 1. Top, Profiles of thyroid volume assessed by B-mode US at baseline and at 1-, 3-, 6-,
and 12-month follow-up in patients treated with RTA (group A) and untreated patients
(group B). Bottom, Profile of thyroid volume assessed by B-mode US at baseline and at 1-, 3-,
6-, and 12-month follow-up in patients treated with RTA (group A) with toxic and nontoxic
TNs.
J Clin Endocrinol Metab, December 2012, 97(12):0000–0000 jcem.endojournals.org 3
Nodule volume
After treatment, TN volume significantly decreased in
group A (8.3  1.2 ml at 1 month, 5.7  0.9 ml at 3
months, 3.2 0.6 ml at 6 months, and 1.8 0.3 ml at 12
months; P  0.0001), whereas it remained unchanged in
group B [11.2  1.5 ml at 1 month, 11.3  1.5 ml at 3
months, 11.4 1.5 ml at 6 months, and 11.8 1.5 ml at
12months;Pnot significant (NS)] (Fig. 1). At 3-, 6-, and
12-month evaluations,TNvolumewas significantly lower
in group A than in group B (P 0.005) (Fig. 2). In group
A, the mean percentage decrease of TN volume progres-
sively increased during the study period, from 36.5 
2.9% at 1 month to 57.3  2.5% at 3 months to 76.5 
2.7% at 6 months and 84.9  1.5 at 9 months.
In group A, TN volume decreased significantly in the
subgroups of patients with both nontoxic and toxic TNs
(Figs. 1 and 2).
Symptoms score and clinical evaluation
SYS score progressively improved in group A from
3.4  0.3 at baseline to 0.6  0.1 at the 12-month eval-
uation (P 0.001), whereas it worsened in group B from
3.0  0.3 at baseline to 4.1  0.2 at the 12-month eval-
uation (P  NS) (Fig. 3).
Hormonal evaluation
After treatment, hormonal parameters did not change
at any follow-up time. All of the patients in group A who
were euthyroid at baseline had normal
serum thyroid function tests after 1, 3,
6, and12months,whereas twopatients
in group Bwhowere euthyroid at base-
line experiencedamilddecreaseofTSH
serum levels consistentwitha condition
of subclinical hyperthyroidism. No sig-
nificant changes were observed in both
groups either in TgAb and TPOAb ti-
ters or in calcitonin serum concentra-
tions during the follow-up period.
In the subgroup of patients with
toxic TNs in group A, hyperthyroidism
completely recovered in four of 10
(40%), as demonstrated by stable eu-
thyroidism after methimazole with-
drawal, and improved in four of 10
(40%) as demonstrated by stable eu-
thyroidism after methimazole reduc-
tion after RTA. Methimazole therapy
was progressively decreased after RTA
by halving the initial dose from d 15. In
case of stable euthyroidism at the ex-
pected time point, then the dose of me-
thimazole was further halved and so on
up to the suspension of the drug. In case of appearance of
hormonal signs of hyperthyroidism after dose reduction,
the previous dose was restored. On the contrary, hyper-
thyroidism persisted unchanged in all (100%) patients
with toxic TNs in group B that continued therapy with
methimazole for the whole 12-month follow-up period.
The mean dose of methimazole was progressively re-
duced in group A from 6.5 mg/d at baseline to 4.3 mg/d at
1 month, 2.4 mg/d at 3 months, and 2.3 mg/d at 6 and 12
months.
Side effects
In all patients in group A, RTA was safe and well tol-
erated. No significant side effects were observed, and no
patient needed hospitalization after treatment.
Local anesthesia prevented pain on needle insertion
and fiber positioning. During the RTA procedure, all
patients were asymptomatic, with the exception of a
mild sensation of heat in the neck that never required
interrupting the procedure. Patients who had under-
gone RTA were placed under observation for about 2 h
after the procedure; no local edema, pain, or other ad-
verse event has been detected.
Discussion
This is the first comparative prospective study evaluating
the long-term efficacy and safety of RTA for both toxic
FIG. 2. Top, TN volume (mean  SEM) at baseline and 1-, 3-, 6-, and 12-month follow-up in
patients treated with RTA (group A) and in untreated patients (group B). Bottom, left, TN
volume (mean  SEM) at baseline and 1-, 3-, 6-, and 12-month follow-up in patients with
toxic TNs treated with RTA vs. untreated patients. Bottom, right, TN volume (mean  SEM) at
baseline and 1-, 3-, 6-, and 12-month follow-up in patients with nontoxic TNs treated with
RTA vs. untreated patients. *, P  0.005; **, P  0.0001, group A vs. group B.
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andnontoxic TNs. Themain finding of this studywas that
RTA significantly decreases TN volume in comparison
withuntreatedpatientswhodonot experienceanyTNsize
decrease or symptom improvement.
A recent study evaluated the effectiveness of RTA in
reducing TN volume by comparing treatment and control
groups (22). This study was performed by using a single-
hook 18-gauge needle in 15 patients while 15 comparable
subjects served as untreated controls. The study popula-
tion included benign, nontoxic, small TNs, which were
predominantly solid but with cystic components up to
40%. A 6-month follow-up highlighted that the observed
TN volume shrinkage was related to RTA activity rather
than spontaneous reduction (22).
The current study was performed by using a four-
hook expandable needle in 20 patients with benign,
both toxic and nontoxic, solid or predominantly solid
(but with cystic component  30%), and large (4.0
ml) TNs and compared them with 20 untreated con-
trols. A long-term 12-month follow-up was performed.
This study population and study design well describe
the effectiveness of RTA on benign TNs and the poten-
tial of this procedure. RTA highly impacts on TN clin-
ical course, inducing a size decrease in all cases and
maintaining the results for a long time after treatment.
On the other hand, untreated patients had no decrease
in TN in any case.
It has to be underlined that cytolog-
ical evaluation of TNs may result in
false-negative diagnoses. This is a lim-
itation for every nonsurgical treatment
of TNs, especially for procedures that,
by causing tissue damage, limit the use-
fulness of repeated fine-needle aspira-
tion. That is why a very accurate mor-
phological evaluation of TNs treated
with RTA has a central role in the cur-
rent study, as in similar studies to ob-
serve the long-term evolution and the
clinical behavior of TNs.
Percutaneous ethanol therapy has
been largely used to ablate solid, non-
functioning TNs. The procedure is cur-
rently abandoned because of both a lack
of evidence of long-term efficacy and re-
ports of pain and other serious adverse
effects related to seepage of ethanol into
perinodular thyroid tissue (1, 9, 25). The
present indication for percutaneous eth-
anol therapy, therefore, is the treatment
of thyroid cysts and of predominantly
cystic nodules, because of its efficacy and
the rare adverse effects (9, 26).
Laser ablation is a thermal technique proposed to treat
TNs. Laser ablation induces a 40–60% decrease in the
size of TNs over a 6-month period, with stable values
during longer-term follow-up. Laser ablationmay require
more than one session and/or the insertion of multiple
optic fibers for treating large TNs. This procedure as well
may be associated with an increased risk of local adverse
events, especially during the training period (16, 27–29).
So far, controlled head-to-head studies comparing the
cost-effectiveness of the various mini-invasive procedures
are lacking. A recent uncontrolled study comparing RTA
to laser ablation concluded that the effectiveness of RTA
seems to be slightly superior to laser ablation, and the
adverse effects somewhat fewer (30). However, laser ab-
lation has proved to be effective in prospective random-
ized and in multicenter trials and, when performed in ex-
perienced centers, is a rapid, inexpensive, and safemethod
for inducing a clinically significant nodule debulking.
In patients with symptomatic, benign, multinodular
goiter, radioactive iodine can achieve a reduction of about
40% in goiter size within 1 yr (dependent on dose). How-
ever, this success comes at the expense of a hypothyroid-
ism rate of about 10–20% (9, 31). For patients with a
solitary toxic or pretoxic TN, radioiodine is considered to
be first-choice treatment. In the vast majority of patients,
FIG. 3. Top, Symptoms score (mean  SEM) expressed as the sum of the single scores
including pressure symptoms in the neck, difficulty in swallowing, esthetic complaint in
patients treated with RTA (group A) and in untreated patients (group B) before and at 1-, 3-,
6-, and 12-month follow-up. Bottom, left, Symptoms score (mean  SEM) at baseline and at
1-, 3-, 6-, and 12-month follow-up in patients with toxic TNs treated with RTA (group A) vs.
untreated patients. Bottom, right, Symptoms score (mean  SEM) at baseline and at 1-, 3-, 6-,
and 12-month follow-up in patients with nontoxic TNs treated with RTA (group A) vs.
untreated patients. *, P  0.005; **, P  0.0001, group A vs. group B.
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one dose is sufficient to cause a 30–40% size reduction
and normalization of thyroid function (9, 25).
Medical therapy with levothyroxine to decrease serum
TSH levels in patients with small nonfunctioning TNs
achieves very limited, if any, goiter shrinkage and is no
longer recommended for routine use in elderly patients
and in postmenopausal women because of the adverse ef-
fects of subnormal serum TSH levels, especially on bone
and the cardiovascular system (9, 32).
The clinical response to RTA is as effective as the ul-
trasonographic response. TN-related compressive symp-
toms rapidly improved after RTA, whereas they persisted
or worsened in untreated patients. Compressive symp-
toms were decreased by about 30% at 1 month, by about
50% at 3 months, by about 70% at 6 months, and more
than 80% 12 months after treatment with RTA. Percuta-
neous ethanol injection seems to be highly effective for the
treatment of cystic TNs, and compressive and cosmetic
symptoms seem to disappeared in up to 80% of patients
(33). Poor data regarding changes in compressive symp-
toms after laser therapy are available.
Patients with toxic TNs were also evaluated. In the
present study, an improvement of hyperthyroidism and
a consequent decrease or withdrawal of methimazole
therapy was observed in 80% of cases. Radioiodine
therapy has proved to be effective in functioning goiter
function (9, 25). In patients with toxic TNs refusing
radioiodine therapy, a decrease of nodule volume and
normalization of serum TSH levels may be observed
after percutaneous ethanol injection (34, 35). Laser
thermal ablation also seems to be effective to induce
improvement of hyperthyroidism (27).
In the present study, no changes in titers of TgAb and
TPOAb or thyroid hormones were observed after RTA in
euthyroid patients, thus indicating that this approach is
not associated with the development of thyroid autoim-
munity or hypothyroidism. On the other hand, hypothy-
roidism, hypoparathyroidism, and recurrent nerve lesions
may follow surgery, which could represent difficult con-
ditions tomanage, especially in elderly patients with other
comorbidities (6). Radioiodine treatment seems to be as-
sociated with increased cardiovascular and cancer mor-
tality, and postradioiodine hypothyroidism occurs in up
to 60% after 20 yr (6, 36, 37).
RTA has been recently used for locoregional control of
metastatic well-differentiated thyroid carcinoma in pa-
tients for whom surgery is not feasible (38). This may
represent a new potential use of RTA, further expanding
the indications of this innovative approach for thyroid
diseases.
In conclusion, RTA is a new therapeutic approach for
themanagementofTNs that is able to control their growth
and to improve both compressive and functioning symp-
toms. RTA represents a valid approach in patients with
TNs who are not candidates, who refuse, or who failed to
be cured by conventional treatments. Larger series and
longer follow-up are needed to confirm the safety and
effectiveness of RTA in the treatment of TNs.
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